UK Devicemaker Warned by FDA on Documentation, Design Changes

May 18, 2012

Amplivox, a UK subsidiary of Danish company William Demant, got a stern warning from the FDA following a December inspection of its Oxford manufacturing plant.

The May 2 letter cites Amplivox with a total of 10 violations, mostly tied to flawed procedures or documentation. Amplivox makes audiometers, spirometers, vision screeners and other occupational health products.

Amplivox did not have adequate procedures in place to identify, document and validate design changes before they were implemented. Nor did its device design methods include proper design validation, complete with risk analysis. 

Design control problems are a common shortcoming behind FDA warning letters. In 2010, 49 of 89 FDA warning letters included them as a concern, CDRH Office of Compliance Director Steve Silverman said at a recent industry conference.

Impress the FDA at your next inspection with FDAnews’ Change Control: Best Practices for FDA-Compliant Medical Device Manufacturers, an in-depth management report that delivers industry-targeted guidance on change control, specifically for medical device manufacturers.

Get the inside scoop on medical device regulatory and ISO standard requirements for change control, including how to:

  • Decipher the FDA’s new Quality System Guidance as it relates to change control;
  • Discover expert-recommended FDA guidance documents and resources on change control; and
  • Put into use the ISO standard requirements concerning change control.

Stay one step ahead when you know the “trouble spots” where change control problems commonly occur — and how they’ll affect you. Order your copy today.